Cost Effectiveness of 5-Alpha Reductase Inhibitors for the Prevention of Prostate Cancer in Multiple Patient Populations
- First Online:
- 70 Downloads
Background: Although 5-alpha reductase inhibitors (5ARIs) have demonstrated that they reduce the risk of prostate cancer (PCa), they have not demonstrated cost effectiveness in the patient populations in which they have been examined.
Objective: A decision-analytic model was created to explore economic benefits from a third-party payer perspective of the use of 5ARIs in preventing PCa in men with different risk factors for developing the disease.
Methods: A Markov model was developed to simulate a cohort of men annually through health states (e.g. healthy male, benign prostatic hyperplasia [BPH], PCa, PCa recurrence) over a man’s lifetime. Men with risk factors were treated with a 5ARI and compared with patients given no chemoprevention. Men from the general population were examined along with higher-risk men who had been referred to a PCa centre. Baseline risk was estimated via published risk data, risk factor analyses and risk equations. Clinical efficacy,morality, costs and utilities were obtained from published literature. Outcomes of the model included number of prostate cancers, incremental costs, incremental QALYs, incremental cost per QALY and number needed to treat. Along with sensitivity and scenario analyses, a validation of outcomes was performed. All costs were valued in $US, year 2009 values. Costs were discounted at 3% per annum.
Results: Men receiving 5ARIs benefited through a reduction in the number of PCas. Assuming a cost-effectiveness threshold of $US50 000 per QALY, chemoprevention with 5ARIs was cost effective ($US37 900 per QALY) in men from the general population who were aged 50 years with elevated prostate-specific antigen (PSA), and who were aged 50 years with PCa family history and elevated PSA ($US31 065 per QALY). Chemoprevention with 5ARIs was not cost effective in men aged 50 years with no additional risk factors, men aged 50 years with abnormal digital rectal examinations (DREs), and men aged 50 years with a family history ($US86 511, $US85 577 and $US84 950 per QALY, respectively). In higher-risk men, chemoprevention could be expected to be cost effective ($US18 490 to $US11 816 per QALY, depending on risk scenario). Results were sensitive to changes in utilities, assumed PCa risk reduction with 5ARIs, and patient age.
Conclusion: When considering common risk factors associated with PCa, prevention with 5ARIs is expected to be cost effective in 50-year-old men with elevated PSA. As a man’s risk increases, the cost effectiveness of 5ARI chemoprevention improves.
- 2.National Cancer Institute. Common cancer types [online]. Available from URL: http://www.cancer.gov/cancertopics/commoncancers [Accessed 2009 Jun 24]
- 3.American Cancer Society. Cancer facts and figures 2009. Atlanta (GA): American Cancer Society, 2009Google Scholar
- 9.Jack A. Cancer drug boost for Glaxo. Financial Times 2009 Apr 28 [online]. Available from URL: http://www.ft.com/cms/s/0/cf252cf6-337f-11de-8f1b-00144feabdc0.html?nclick_check=1 [Accessed 2009 Jun 15]
- 14.Weinstein MC. From cost-effectiveness ratios to resource allocation: where to draw the line. In: Sloan FA, editor. Valuing health care: costs, benefits, and effectiveness of pharmaceuticals and other medical technologies. New York: Cambridge University Press, 1995Google Scholar
- 17.Black L, Naslund MJ, Gilbert TD, et al. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006; 12: S99–110Google Scholar
- 18.Finasteride. Proscar [package insert]. Whitehouse Station (NJ): Merck & Co., Inc, 2007Google Scholar
- 19.Dutasteride. Avodart [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2005Google Scholar
- 20.National Vital Statistics Reports. Deaths: final data for 2005. Table 5: number of deaths and death rates by age, and age-adjusted death rates, according to specified Hispanic origin, race for non-Hispanic population, and sex. United States. Natl Vital Stat Rep 2005; 56 (10)Google Scholar
- 24.Lefkowitz GK, Taneja SS, Brown J, et al. Follow-up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 2000; 168 (4 Pt 1): 1415–8Google Scholar
- 28.Roobol M, Erasmus MC. Modelling determinants of prostate cancer risk: analyses of the ERSPC, Section Rotterdam database, version 2.1. Research Triangle Park (NC): GlaxoSmithKline, 2006 Oct 22. (Data on file)Google Scholar
- 29.National Cancer Data Base. Benchmark reports (v2.0) [online]. Available from URL: http://cromwell.facs.org/BMarks/BMPub/Ver10/DxRx/BMPub_DxRx.cfm [Accessed 2009 Jun 24]
- 35.Micromedex, Inc. Red book. Vol. 52. Greenwood Village (CO): Micromedex, Inc., 2009Google Scholar
- 36.American Medical Association. Current procedural terminology CPT 2001. Chicago (IL): AMA Press, 2008Google Scholar
- 37.Ingenix, Inc. The essential RBRVS: a comprehensive listing of RBRVS values for CPT and HCPCS codes. Eden Prairie (MN): St. Anthony Publishing (Ingenix), 2008Google Scholar
- 44.US Department of Labor, US Bureau of Labor Statistics. US city average, not seasonally adjusted medical care [online]. Available from URL: http://data.bls.gov/PDQ/outside.jsp?survey=cu [Accessed 2009 Jun 24]
- 46.Data on file, GlaxoSmithKline, 2008 Apr 30Google Scholar
- 48.Walgreens [online]. Available from URL: http://www.walgreens.com [Accessed 2009 Jun 15]
- 53.Roehrborn CG, McConnell JD, Barry MJ, et al. for the Benign Prostatic Hyperplasia (BPH) Guideline Update Panel of the American Urological Association Education and Research, Inc. Guideline on the management of benign prostatic hyperplasia (BPH), updated 2006 [online]. Available from URL: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/bph-management/chapt_4_appendix.pdf [Accessed 2009 Jun 24]
- 54.Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996Google Scholar
- 55.Surveillance, Epidemiology, and End Results program. SEER*Stat databases: incidence-SEER 13 Regs publicuse, November 2004 sub for expanded races (1992–2002), and incidence-SEER 13 Regs excluding AK public-use, November 2004 sub for Hispanics (1992–2002), released April 2005 [online]. Available from URL: http://canques.seer.cancer.gov/cgi-bin/cq_submit?dir=seer2002&db=4&rpt=TAB&sel=1^0^62^1^1^&dec=4&title=Age-specific%20(Crude)%20SEER%20Incidence%20Rates%20by%20Expanded%20Race~For%20Prostate%20Cancer,%20Males~SEER%2013%20Registries%20for%201998-2002&template=faststats&x=Age%20at%20diagnosis^2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20&y=Race/ethnicity^1,2,3,4 [Accessed 2009 Jun 24]
- 57.National Cancer Institute. Statistical Research and Applications. Surveillance, Epidemiology, and End Results programme. Cancer Query System: probability of developing or dying of cancer [online]. Available from URL: http://srab.cancer.gov/devcan/canques.html [Accessed 2008 Feb 6]
- 58.Andriole GL, Pettaway CA, Teloken C, et al. Incidence of biopsy-detectable prostate cancer in the Reduction of Dutasteride of Prostate Cancer Events (REDUCE) trial: blinded 2-year results [presentation]. Annual Meeting of the American Urological Association; 2009 Apr 25-30; Chicago (IL)Google Scholar